Silexion Therapeutics' Preclinical Success Boosts Stock by Over 100%
Silexion Therapeutics Corp. (NASDAQ: SLXN) is experiencing a remarkable surge in its stock price, jumping 108.6% in premarket trading to reach a price change of +0.63. This dramatic increase follows the release of compelling preclinical data regarding its new therapeutic candidate, SIL-204, aimed at treating KRAS-driven pancreatic cancer.
On January 28, 2025, the company announced that SIL-204 demonstrated promising results in reducing tumor growth in preclinical models. Specifically, the research revealed that the systemic administration of SIL-204 resulted in approximately a 50% reduction in tumor size over 30 days in models simulating human pancreatic cancers. Such findings are crucial for validating the effectiveness of SIL-204 in targeting difficult-to-treat cancers.
The data from Silexion details that over half of the tumors treated showed complete necrosis, marking a substantial advancement in the area of therapeutics for pancreatic cancer—a type noted for its aggressive nature and challenging prognosis. These results not only highlight the therapeutic potential of SIL-204 but also indicate the company's capability to innovate in the oncology sector.
Furthermore, the study underscored SIL-204's ability to target various KRAS mutations, which are increasingly recognized as critical drivers in numerous cancers. Silexion's commitment to developing next-generation RNA interference therapies positions it favorably among its peers in the biotechnology field.
As Silexion Therapeutics prepares to refine its treatment strategies based on this preclinical data, investors are eagerly anticipating additional information that could further confirm the effectiveness and potential clinical applications of SIL-204. With trading volumes soaring at 46.1 million shares, it is evident that the market is responding positively to the news.
For investors and those monitoring the biotechnology sector, Silexion’s progress highlights the dynamic nature of clinical-stage companies and their potential for rapid stock price movements based on scientific breakthroughs.
